Consistently, we have previously found that Lkb1 inactivation is able to drive lung cancer AST in the KrasG12D-based genetically engineered mouse models (GEMM).23,27–29 These pathologically transitioned mouse tumors also display therapeutic resistance to multiple inhibitors initially effective in lung ADC,29 similar to the clinical observations. This evidence concerns the gene STK11 and lung cancer.